# A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

> **NCT01347580** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1875 (actual)

## Conditions studied

- Myocardial Infarction
- Segment Elevation Myocardial Infarction (STEMI)

## Interventions

- **DRUG:** Ticagrelor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01347580
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 1875 (ACTUAL)
- **Last updated:** 2015-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01347580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01347580, "A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01347580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*